Abstract
Triple-negative breast cancer (TNBC) remains a therapeutic challenge despite multi-drug strategies with cytotoxics and targeted agents. As such, novel compounds with potent efficacy against TNBCs in vitro and in vivo represent an area of significant developmental interest. Natural withanolides derived from the North American Physalis plant exhibit potent anticancer effects against multiple tumor types. We hypothesize that these novel withanolides are a potent therapy for TNBC in vivo through a redefined mechanism of oxidation and apoptotic cell death.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
